TY - JOUR
T1 - Characterization of new allergens from the venom of the european paper wasp polistes dominula
AU - Grosch, Johannes
AU - Eberlein, Bernadette
AU - Waldherr, Sebastian
AU - Pascal, Mariona
AU - Bartolomé, Clara San
AU - De La Roca Pinzón, Federico
AU - Dittmar, Michael
AU - Hilger, Christiane
AU - Ollert, Markus
AU - Biedermann, Tilo
AU - Darsow, Ulf
AU - Bilò, Maria Beatrice
AU - Schmidt-Weber, Carsten B.
AU - Blank, Simon
N1 - Funding Information:
Funding: This research was funded by the Helmholtz Association, Future Topic “Immunology and Inflammation”, grant number ZT-0027 to S.B. and C.B.S.-W.
Funding Information:
Conflicts of Interest: U.D., F.D.L.R.P., M.D., J.G., C.H., M.P., C.S.B., S.W. declare no conflict of interest. M.B.B. reports personal fees from ALK-Abelló, outside the submitted work. B.E. reports non-financial support from the company BÜHLMANN laboratories AG (Schönenbuch, Switzerland). MO reports personal fees from Hycor Diagnostics, outside the submitted work. T.B. gave advice to or got a honorarium for talks or research grant from Alk-Abelló, Mylan and Phadia-Thermo Fisher, outside the submitted work. C.B.S.-W. reports personal fees from Bencard, personal fees from Allergopharma, outside the submitted work. S.B. reports non-financial support from ALK-Abelló, grants and personal fees from Bencard Allergie GmbH, personal fees from Teomed AG, grants and personal fees from Thermo Fisher Scientific, grants from Allergy Therapeutics, grants from LETI Pharma, outside the submitted work.
Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021/8/10
Y1 - 2021/8/10
N2 - Discriminating Polistes dominula and Vespula spp. venom allergy is of growing importance worldwide, as systemic reactions to either species’ sting can lead to severe outcomes. Administering the correct allergen-specific immunotherapy is therefore a prerequisite to ensure the safety and health of venom-allergic patients. Component-resolved diagnostics of Hymenoptera venom allergy might be improved by adding additional allergens to the diagnostic allergen panel. Therefore, three potential new allergens from P. dominula venom—immune responsive protein 30 (IRP30), vascular endothelial growth factor C (VEGF C) and phospholipase A2 (PLA2)—were cloned, recombinantly produced and biochemically characterized. Sera sIgE titers of Hymenoptera venom-allergic patients were measured in vitro to assess the allergenicity and potential cross-reactivity of the venom proteins. IRP30 and VEGF C were classified as minor allergens, as sensitization rates lay around 20–40%. About 50% of P. dominula venom-allergic patients had measurable sIgE titers directed against PLA2 from P. dominula venom. Interestingly, PLA2 was unable to activate basophils of allergic patients, questioning its role in the context of clinically relevant sensitization. Although the obtained results hint to a questionable benefit of the characterized P. dominula venom proteins for improved diagnosis of venom-allergic patients, they can contribute to a deeper understanding of the molecular mechanisms of Hymenoptera venoms and to the identification of factors that determine the allergenic potential of proteins.
AB - Discriminating Polistes dominula and Vespula spp. venom allergy is of growing importance worldwide, as systemic reactions to either species’ sting can lead to severe outcomes. Administering the correct allergen-specific immunotherapy is therefore a prerequisite to ensure the safety and health of venom-allergic patients. Component-resolved diagnostics of Hymenoptera venom allergy might be improved by adding additional allergens to the diagnostic allergen panel. Therefore, three potential new allergens from P. dominula venom—immune responsive protein 30 (IRP30), vascular endothelial growth factor C (VEGF C) and phospholipase A2 (PLA2)—were cloned, recombinantly produced and biochemically characterized. Sera sIgE titers of Hymenoptera venom-allergic patients were measured in vitro to assess the allergenicity and potential cross-reactivity of the venom proteins. IRP30 and VEGF C were classified as minor allergens, as sensitization rates lay around 20–40%. About 50% of P. dominula venom-allergic patients had measurable sIgE titers directed against PLA2 from P. dominula venom. Interestingly, PLA2 was unable to activate basophils of allergic patients, questioning its role in the context of clinically relevant sensitization. Although the obtained results hint to a questionable benefit of the characterized P. dominula venom proteins for improved diagnosis of venom-allergic patients, they can contribute to a deeper understanding of the molecular mechanisms of Hymenoptera venoms and to the identification of factors that determine the allergenic potential of proteins.
KW - Allergen
KW - Allergen cross-reactivity
KW - Hymenoptera venom allergy
KW - Phospholipase A2
KW - Polistes dominula
UR - http://www.scopus.com/inward/record.url?scp=85112774580&partnerID=8YFLogxK
UR - https://www.ncbi.nlm.nih.gov/pubmed/34437431
U2 - 10.3390/toxins13080559
DO - 10.3390/toxins13080559
M3 - Article
C2 - 34437431
AN - SCOPUS:85112774580
SN - 2072-6651
VL - 13
JO - Toxins
JF - Toxins
IS - 8
M1 - 559
ER -